Skip to main content
Shingrix brand logo
Proper Name
Zoster Vaccine Recombinant, Adjuvanted
Indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older.

SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted) is a sterile suspension for intramuscular injection. The vaccine is supplied as a vial of lyophilized recombinant varicella zoster virus surface glycoprotein E (gE) antigen component, which must be reconstituted at the time of use with the accompanying vial of AS01B adjuvant suspension component.

Key Regulatory Milestones

05/17/2019 - FDA approval date

Advanced Facts